biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
biote Corp.NASDAQ: BTMD
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $96K (cash outflow) fell 89.4% year over year, ahead of the -92.0% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -15.0% a year.
Context
- Accounts receivables amounted to 0.5% of revenue in FY2025, down 0.7 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -89.4% holds above the trailing-twelve-month pace of -92.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (958K) USD
- Year-over-year change
- +57.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (958K) | +57.7% |
| FY2024 | 2024-12-31 | (2.27M) | -348.9% |
| FY2023 | 2023-12-31 | (505K) | +67.7% |
| FY2022 | 2022-12-31 | (1.56M) | -107.7% |
| FY2021 | 2021-12-31 | (752K) | — |
Accounts Receivables vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 accounts receivables of $147K is the 8th largest of the 11 companies compared; the peer median is $165.82K.
- Its year-over-year change of -92.0% is the 7th highest of 8, against a peer median of -48.1%.
- Accounts receivables amounts to 0.1% of revenue for BTMD, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.81M | -273.1% | — | 4.1% | |
| LTM Mar 2026 | $2.53M | +162.9% | — | 220.4% | |
| LTM Mar 2026 | $2.42M | -48.1% | — | 7.2% | |
| LTM Mar 2026 | $631K | +5158.3% | — | 12.3% | |
| LTM Mar 2026 | $624K | -85.7% | +25.5% | 1.1% | |
| LTM Mar 2026 | $532.37K | +183.8% | — | 0.9% | |
| LTM Mar 2026 | $331.65K | -73.3% | — | — | |
| LTM Mar 2026 | $147K | -92.0% | -15.0% | 0.1% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding BTMD) | $165.82K | -48.1% | +25.5% | 5.6% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 32.62M | 1.32M | 3.32M | 46K | 27.05M |
| Depreciation & Amortization | 1.4M | 2.2M | 2.99M | 3.57M | 3.67M |
| Deferred Income Tax | 0 | (743K) | 721K | (2.9M) | 3.98M |
| Stock-Based Compensation | 0 | 82.18M | 9.06M | 8.74M | 8.92M |
| Change in Working Capital | (1.46M) | (35.81M) | (8.93M) | 9.93M | (8.25M) |
| Accounts Receivables | (752K) | (1.56M) | (505K) | (2.27M) | (958K) |
| Inventory | (5.76M) | (1.71M) | (6.1M) | 3.71M | (6.24M) |
| Accounts Payables | 1.61M | 416K | (165K) | 1.55M | 1.01M |
| Other Working Capital | 3.45M | (32.96M) | (2.16M) | 6.94M | (2.06M) |
| Other Non-Cash Items | 1.16M | (58.3M) | 19.72M | 25.85M | (165K) |
| Operating Cash Flow | 33.72M | (9.16M) | 26.88M | 45.24M | 35.19M |
| Capital Expenditures | (3.81M) | (1.84M) | (2.71M) | (6.43M) | (5.02M) |
| Acquisitions (Net) | 0 | 0 | 0 | (11.84M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2.36M) | (1.51M) | (2.35M) | (526K) | (1.85M) |
| Investing Cash Flow | (3.81M) | (1.84M) | (2.71M) | (18.8M) | (6.86M) |
| Debt Repayment | (5M) | 84.38M | (6.25M) | (6.25M) | (1.25M) |
| Common Stock Issued | 0 | 442K | 144K | 282K | 368K |
| Common Stock Repurchased | 0 | (424K) | 0 | (5.6M) | (3.37M) |
| Dividends Paid | (11.4M) | (12.89M) | (8.69M) | (4.74M) | (1.73M) |
| Other Financing Activities | (3.94M) | (8.05M) | 420K | (59.77M) | (37.58M) |
| Financing Cash Flow | (20.34M) | 63.46M | (14.38M) | (76.08M) | (43.56M) |
| Effect of Forex Changes | (12K) | 0 | (19K) | (22K) | 6K |
| Net Change in Cash | 9.56M | 52.47M | 9.77M | (49.66M) | (15.22M) |
| Free Cash Flow | 29.91M | (11M) | 24.17M | 38.81M | 30.18M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.